Dyslipidemia

A prespecified analysis of FOURIER is detailing the impact of evolocumab on CV events and LDL-C in patients with metabolic syndrome.

A new network meta-analysis offers an overview of the clinical benefit of less than 6 months, 6-month, 12-month, and extended periods of DAPT therapy after PCI with drug-eluting stents.

S. Claiborne Johnston discusses the results of the phase 3 THALES trial examining use of ticagrelor dual antiplatelet therapy for reducing subsequent stroke in patients with AIS or TIA.

A prespecified analysis of ISAR-REACT 5 is shedding light on the effectiveness and safety of age- and weight-adjusted prasugrel versus ticagrelor following ACS.

A secondary ACCELERATE assessment shows a particular set of patients who may benefit from Lp(a)-lowering novel agents.

Results of the phase 3 THALES trial detail the effect of ticagrelor DAPT for reducing the risk of stroke and death in patients with acute ischemic stroke or transient ischemic attack.

New data suggests heparin could mitigate SARS-CoV-2 ability to bind to human cells.

The practice of genetic testing has been useful in clinically addressing found cases of familial hypercholesterolemia, among other conditions, but no clinical practice guidelines currently exist for testing patients with suspected hereditary dyslipidemia.

An observational study in Sweden is challenging current guidelines in regard to preference of ticagrelor over clopidogrel for patients with ACS undergoing PCI.

New research is detailing the impact of statin use for primary prevention in elderly patients free from atherosclerotic cardiovascular disease.

While often referred to as "Good cholesterol" new research suggests HDL measurements do little for predicting risk of heart attack in Black patients

Discussing how advances in care and therapeutic agents have impacted the management of diabetes in 2020.

Deepak Bhatt, MD, MPH, discusses the results of the latest REDUCE-IT analysis, titled REDUCE-IT DIABETES, presented at ADA 2020.

A new study from the University of Arizona is shedding light on the psychological impact of Tai Chi in patients with cardiovascular disease.

A new analysis examines impact of treatment adherence in more than 1.2 million patients.

The expanded indication is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy in those with a high risk, but no history of heart attack or stroke.

Discussing the results of a recent analysis that estimated the impact of comprehensive therapy with SGLT2 inhibitors, ARNIs, and MRAs in patients with HFrEF.

The latest scientific statement from the American Heart Association examines disparities in risk factors, social determinants of health, and management approaches for these patients.

The move comes less than 3 months after a United States District Court for the District of Nevada invalidated 6 Vascepa patients owned by Amarin.

A new analysis of the DASH trial found a fruit-and-vegetable diet was associated with lower levels of hs-cTnl and NT-proBNP.

A six-month study shows the common OSA therapy could have long-term benefit for reducing eventual cardiovascular risk.

A new analysis of 28 studies including more than 90k patients suggests 1-in-10 of these conditions is misdiagnosed, results in delays in treatment and potential harm.

Data presented at SCAI 2020 examining a novel cell therapy suggests it could help reduce angina in patients with non-obstructive coronary artery disease.

An analysis of the TWILIGHT trial presented at SCAI examines SYNERGY BP-EES in a high-risk patient population.

Results of the latest REDUCE-IT analysis shed light on the degree to which icosapent ethyl can reduce revascularization.

New research suggests consuming just one sugar-sweetened beverage per day increases risk of CVD by nearly 20% in women.

A new research letter has found declines in rural areas have not been as pronounced as declines in metropolitan areas.

The latest scientific statement from the association highlights the importance of healthy diet at a young age on preventing CVD later in life.

Discussing the impact of high-intensity statin therapy on patients with dry AMD with a study investigator from Byers Eye Institute.

A new analysis of two-year data from the FOURIER trial is shedding light on the impact of PCSK9 use for lowering LDL-C.